{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:11:54Z","timestamp":1789103514515,"version":"build-2803163510"},"reference-count":64,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV -006739"],"award-info":[{"award-number":["INV -006739"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>\n                    Adverse drug reactions (ADRs) remain a major barrier to successful tuberculosis (TB) treatment. They undermine adherence, prolong morbidity, and increase the risk of treatment failures and mortality. Yet, evidence on their incidence, duration, and management across diverse patient groups remains limited. We conducted a mixed-methods study to address this gap, using a representative sample of patients from six states in India. Specifically, we combined ethnographic observations and interviews with patients and stakeholders (n = 40) across three districts with a quantitative survey of 2,124 randomly selected TB patients across eight districts. The ethnographic analysis revealed a novel taxonomy of ADRs, distinguishing\n                    <jats:italic>active ADRs<\/jats:italic>\n                    (acute, clinically urgent conditions), from\n                    <jats:italic>passive ADRs<\/jats:italic>\n                    (persistent, lower-intensity conditions) that quietly undermine adherence in later treatment phases. Passive ADRs such as skin darkening and fatigue typically warrant little clinical attention, yet their persistence makes them highly relevant for patient management strategies aimed at supporting adherence and achieving TB elimination. This finding was further contextualized and strengthened by quantitative analysis, which provided robust statistical insights into their incidence across diverse patient profiles. The quantitative analyses also reveal a near-universal burden of ADRs, with 86% of patients reporting at least one ADR (Mean\u2009=\u20093.1, SD 2.38). Women reported ADRs more frequently and for longer durations, particularly cutaneous ADRs, while elderly patients were more prone to gastrointestinal and musculoskeletal ADRs. Younger patients and women reported the highest prevalence of vomiting (41%), which emerged as the only independent predictor of unsuccessful treatment completion (OR = 0.39, 95% CI: 0.20\u20130.76). The overall number of ADRs was also strongly correlated with adverse treatment outcomes (OR = 0.88, 95% CI: 0.78\u20130.98). The active-passive taxonomy, along with risk-group profiling, offers a roadmap for differentiated counselling and pro-active patient-centric ADR management. We recommend embedding this approach into national TB protocols, with structured risk-based patient counselling at different stages of treatment, supported by adequate training for treatment coordinators and providers. While further research is warranted to assess scalability and cost-effectiveness, our findings demonstrate both the urgency and the feasibility of structured ADR management in high-burden TB settings.\n                  <\/jats:p>","DOI":"10.1371\/journal.pgph.0004149","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T18:28:45Z","timestamp":1767032925000},"page":"e0004149","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adverse drug reactions in tuberculosis treatment: Incidence, duration and resolution pathways from a mixed-methods patient-centric study in India"],"prefix":"10.1371","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2401-1065","authenticated-orcid":true,"given":"Ridhima","family":"Sodhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9260-2352","authenticated-orcid":true,"given":"Tunisha","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2655-8743","authenticated-orcid":true,"given":"Vindhya","family":"Vatsyayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3674-3885","authenticated-orcid":true,"given":"Iti","family":"Seth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishita","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8514-1014","authenticated-orcid":true,"given":"Manoj","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2161-7520","authenticated-orcid":true,"given":"Arnab","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4530-0694","authenticated-orcid":true,"given":"Shamim","family":"Mannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"pgph.0004149.ref001","author":"World Health Organization","year":"2015"},{"key":"pgph.0004149.ref002","author":"Global Programme on Tuberculosis & Lung Health","year":"2025"},{"issue":"9","key":"pgph.0004149.ref003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pdig.0000421","article-title":"Impact of a pilot mHealth intervention on treatment outcomes of TB patients seeking care in the private sector using Propensity Scores Matching-Evidence collated from New Delhi, India","volume":"3","author":"R Sodhi","year":"2024","journal-title":"PLOS Digit Health"},{"issue":"10","key":"pgph.0004149.ref004","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2024-015654","article-title":"Cost and cost-effectiveness of digital technologies for support of tuberculosis treatment adherence: a systematic review","volume":"9","author":"C Kafie","year":"2024","journal-title":"BMJ Glob Health"},{"issue":"45","key":"pgph.0004149.ref005","article-title":"Impact of mass screening using chest X-ray on mortality reduction and treatment adherence among pulmonary tuberculosis patients","volume":"39","author":"JY Baek","year":"2024","journal-title":"J Korean Med Sci"},{"key":"pgph.0004149.ref006","doi-asserted-by":"crossref","first-page":"04226","DOI":"10.7189\/jogh.14.04226","article-title":"Cost-effectiveness analysis of a prediction model for community-based screening of active tuberculosis","volume":"14","author":"C-C Yang","year":"2024","journal-title":"J Glob Health"},{"issue":"1","key":"pgph.0004149.ref007","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/s12879-023-08396-5","article-title":"Free drug provision for tuberculosis increases patient follow-ups and successful treatment outcomes in the Indian private sector: a quasi experimental study using propensity score matching","volume":"23","author":"R Sodhi","year":"2023","journal-title":"BMC Infect Dis"},{"issue":"4","key":"pgph.0004149.ref008","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/tropicalmed6040206","article-title":"Active case finding for tuberculosis in india: a syntheses of activities and outcomes reported by the national tuberculosis elimination programme","volume":"6","author":"S Burugina Nagaraja","year":"2021","journal-title":"Trop Med Infect Dis"},{"issue":"6","key":"pgph.0004149.ref009","first-page":"569","article-title":"National tuberculosis programme review: experience over the period 1990-95","volume":"75","author":"A Pio","year":"1997","journal-title":"Bull World Health Organ"},{"key":"pgph.0004149.ref010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.tube.2005.08.003","article-title":"Revised national TB control programme in India","volume":"85","author":"LS Chauhan","year":"2005","journal-title":"Tuberculosis (Edinb)"},{"issue":"11","key":"pgph.0004149.ref011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pdig.0000667","article-title":"Facilitators and barriers to uptake of digital adherence technologies in improving TB care in Ethiopia: a qualitative study","volume":"3","author":"Z Shewamene","year":"2024","journal-title":"PLOS Digit Health"},{"issue":"11","key":"pgph.0004149.ref012","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"D Yee","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"pgph.0004149.ref013","first-page":"134","article-title":"Evaluation of anti-tuberculosis induced adverse reactions in hospitalized patients","volume":"4","author":"K Gholami","year":"2006","journal-title":"Pharm Pract (Granada)"},{"issue":"10","key":"pgph.0004149.ref014","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/pds.1468","article-title":"Adverse reactions of anti-tuberculosis drugs in hospitalized patients: incidence, severity and risk factors","volume":"16","author":"MR Javadi","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"pgph.0004149.ref015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0962-8479(96)90073-8","article-title":"Frequency and type of reactions to antituberculosis drugs: observations in routine treatment","volume":"77","author":"LP Ormerod","year":"1996","journal-title":"Tuber Lung Dis"},{"issue":"1","key":"pgph.0004149.ref016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227293","article-title":"Barriers in the access, diagnosis and treatment completion for tuberculosis patients in central and western Nepal: A qualitative study among patients, community members and health care workers","volume":"15","author":"SB Marahatta","year":"2020","journal-title":"PLoS ONE"},{"issue":"1","key":"pgph.0004149.ref017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41043-017-0132-y","article-title":"Factors influencing adherence to tuberculosis treatment in Asmara, Eritrea: a qualitative study","volume":"37","author":"FH Gebreweld","year":"2018","journal-title":"J Health Popul Nutr"},{"key":"pgph.0004149.ref018","article-title":"Prevalence of adverse drug reaction with first-line drugs among patients treated for pulmonary tuberculosis","volume":"3","author":"A Singh","year":"2015","journal-title":"Clin Epidemiol Glob Health"},{"key":"pgph.0004149.ref019","volume-title":"Toman\u2019s tuberculosis: case detection, treatment and monitoring; questions and answers","author":"K. Toman","year":"2004","edition":"2"},{"issue":"4","key":"pgph.0004149.ref020","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ijtb.2019.11.005","article-title":"Adverse drug reactions in tuberculosis and management","volume":"66","author":"R Prasad","year":"2019","journal-title":"Indian J Tuberc"},{"issue":"3","key":"pgph.0004149.ref021","doi-asserted-by":"crossref","first-page":"645","DOI":"10.18203\/2349-3933.ijam20171512","article-title":"Impact of adverse drug reaction of first line anti - tuberculous drugs on treatment outcome of tuberculosis under revised national tuberculosis control programme","volume":"4","author":"AR Dedun","year":"2017","journal-title":"Int J Adv Med"},{"issue":"5","key":"pgph.0004149.ref022","first-page":"529","article-title":"Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India","volume":"133","author":"P Joseph","year":"2011","journal-title":"Indian J Med Res"},{"issue":"3","key":"pgph.0004149.ref023","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ijtb.2016.11.031","article-title":"A study of clinical profile of cases of MDR-TB and evaluation of challenges faced in initiation of second line Anti tuberculosis treatment for MDR-TB cases admitted in drug resistance tuberculosis center","volume":"66","author":"S Mukati","year":"2019","journal-title":"Indian J Tuberc"},{"key":"pgph.0004149.ref024","article-title":"The longer the therapy, the worse the severity of the adverse drug reactions that occur in drug-resistant pulmonary tuberculosis patients","author":"R Susilo","year":"2024","journal-title":"Indian J Tuberc"},{"issue":"8","key":"pgph.0004149.ref025","first-page":"868","article-title":"Adverse drug reactions associated with first-line anti-tuberculosis drug regimens","volume":"11","author":"F Marra","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"pgph.0004149.ref026","first-page":"122","article-title":"Factors associated with spontaneous adverse drug reaction reporting among healthcare professionals in Vietnam","volume":"45","author":"TT Le","year":"2019","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"pgph.0004149.ref027","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00002018-200932010-00002","article-title":"Determinants of under-reporting of adverse drug reactions: a systematic review","volume":"32","author":"E Lopez-Gonzalez","year":"2009","journal-title":"Drug Saf"},{"issue":"4","key":"pgph.0004149.ref028","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1586\/17512433.2015.1053391","article-title":"Pharmacovigilance in resource-limited countries","volume":"8","author":"S Olsson","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"pgph.0004149.ref029","doi-asserted-by":"crossref","DOI":"10.4314\/tjpr.v10i3.4","article-title":"Knowledge, Attitude and Practice of Adverse Drug Reaction Reporting among Healthcare Workers in a Tertiary Centre in Northern Nigeria","volume":"10","author":"J Fadare","year":"2011","journal-title":"Trop J Pharm Res"},{"key":"pgph.0004149.ref030","first-page":"61","article-title":"Awareness among nurses about reporting of adverse drug reactions in Sweden","author":"Petersson, T\u00e5gerud, B\u00e4ckstr\u00f6m","year":"2012","journal-title":"DHPS"},{"key":"pgph.0004149.ref031","volume-title":"Designing and conducting mixed methods research","author":"JW Creswell","year":"2018","edition":"3"},{"key":"pgph.0004149.ref032","volume-title":"An applied guide to research designs: quantitative, qualitative, and mixed methods","author":"TD Kennedy","year":"2017","edition":"2"},{"key":"pgph.0004149.ref033","year":"2021"},{"key":"pgph.0004149.ref034","volume-title":"Patient Provider Support Agency India Toolkit","author":"P.A.T.H","year":"2019"},{"key":"pgph.0004149.ref035"},{"key":"pgph.0004149.ref036","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.12688\/f1000research.125815.2","article-title":"Characteristics and contributing factors of adverse drug reactions: an analytical study of patients with tuberculosis receiving treatment under the National TB Program of India","volume":"11","author":"H Shah","year":"2024","journal-title":"F1000Res"},{"issue":"1","key":"pgph.0004149.ref037","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijtb.2020.01.003","article-title":"\u201cHave we missed reporting adverse drug reactions under Revised National TB Control Programme?\u201d - A mixed method study in Bengaluru, India","volume":"67","author":"L Krishnappa","year":"2020","journal-title":"Indian J Tuberc"},{"issue":"7","key":"pgph.0004149.ref038","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1111\/bcp.15263","article-title":"Identifying and managing adverse drug reactions: qualitative analysis of patient reports to the UK yellow card scheme","volume":"88","author":"B O\u2019 Donovan","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"pgph.0004149.ref039","doi-asserted-by":"crossref","first-page":"801","DOI":"10.18203\/2394-6040.ijcmph20180272","article-title":"Study on the adverse effects affecting treatment outcome in smear positive tuberculosis patients under DOTS in Amritsar city","volume":"5","author":"M Nagpal","year":"2018","journal-title":"Int J Community Med Public Health"},{"issue":"5","key":"pgph.0004149.ref040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019566","article-title":"Incidence and risk factors of serious adverse events during antituberculous treatment in rwanda: a prospective cohort study","volume":"6","author":"N Lorent","year":"2011","journal-title":"PLoS ONE"},{"issue":"6","key":"pgph.0004149.ref041","article-title":"Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study","volume":"8","author":"X Lv","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"pgph.0004149.ref042","article-title":"Impact of adverse drug reactions on the outcomes of tuberculosis treatment","volume":"18","author":"FM Sant Anna","year":"2023","journal-title":"PLoS One"},{"issue":"20","key":"pgph.0004149.ref043","doi-asserted-by":"crossref","DOI":"10.3310\/hta15200","article-title":"Evaluation of patient reporting of adverse drug reactions to the UK \u201cYellow Card Scheme\u201d: literature review, descriptive and qualitative analyses, and questionnaire surveys","volume":"15","author":"AJ Avery","year":"2011","journal-title":"Health Technol Assess"},{"issue":"1","key":"pgph.0004149.ref044","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41598-021-04345-x","article-title":"A systematic review and meta-analysis of the catastrophic costs incurred by tuberculosis patients","volume":"12","author":"RM Ghazy","year":"2022","journal-title":"Sci Rep"},{"issue":"4","key":"pgph.0004149.ref045","doi-asserted-by":"crossref","first-page":"779","DOI":"10.18203\/2319-2003.ijbcp20170941","article-title":"A study of adverse drug reactions among pulmonary tuberculosis patients treated under dots in a tertiary care hospital","volume":"6","author":"GP Bai","year":"2017","journal-title":"Int J Basic Clin Pharmacol"},{"key":"pgph.0004149.ref046","first-page":"412893","article-title":"Adverse reactions to antituberculosis drugs in Iranian tuberculosis patients","volume":"2014","author":"A Farazi","year":"2014","journal-title":"Tuberc Res Treat"},{"key":"pgph.0004149.ref047","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.sapharm.2024.08.091","article-title":"Development and validation of a predictive scoring model for risk stratification of tuberculosis treatment interruption","volume":"20","author":"AL Oh","year":"2024","journal-title":"Res Social Adm Pharm"},{"issue":"5","key":"pgph.0004149.ref048","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1080\/08870446.2011.605886","article-title":"Coping with adverse drug events in patients with heart failure: Exploring the role of medication beliefs and perceptions","volume":"27","author":"RH De Smedt","year":"2012","journal-title":"Psychol Health"},{"issue":"1","key":"pgph.0004149.ref049","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"I Zucker","year":"2020","journal-title":"Biol Sex Differ"},{"issue":"2","key":"pgph.0004149.ref050","doi-asserted-by":"crossref","first-page":"2392883","DOI":"10.1080\/0886022X.2024.2392883","article-title":"Effect of chronic kidney disease on adverse drug reactions to anti-tubercular treatment: a retrospective cohort study","volume":"46","author":"D Datta","year":"2024","journal-title":"Ren Fail"},{"issue":"1","key":"pgph.0004149.ref051","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40266-020-00811-9","article-title":"Safety of pyrazinamide for the treatment of tuberculosis in older patients over 75 years of age: a retrospective monocentric cohort study","volume":"38","author":"S Rousset","year":"2021","journal-title":"Drugs Aging"},{"issue":"3","key":"pgph.0004149.ref052","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"OP Soldin","year":"2009","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"pgph.0004149.ref053","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/00128071-200102060-00001","article-title":"Do women have more adverse drug reactions?","volume":"2","author":"M Rademaker","year":"2001","journal-title":"Am J Clin Dermatol"},{"key":"pgph.0004149.ref054","article-title":"Opportunities and challenges of pharmacovigilance in special populations: a narrative review of the literature","volume":"14","author":"Y Li","year":"2023","journal-title":"Ther Adv Drug Saf"},{"issue":"2","key":"pgph.0004149.ref055","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4103\/2320-8775.123213","article-title":"Adverse drug reactions in tuberculosis patients due to directly observed treatment strategy therapy: Experience at an outpatient clinic of a teaching hospital in the city of Imphal, Manipur, India","volume":"1","author":"K Sinha","year":"2013","journal-title":"J Assoc Chest Physicians"},{"issue":"6","key":"pgph.0004149.ref056","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3390\/jpm12060907","article-title":"Sex-Related differences in pharmacological response to CNS drugs: a narrative review","volume":"12","author":"M Romanescu","year":"2022","journal-title":"J Pers Med"},{"issue":"3","key":"pgph.0004149.ref057","doi-asserted-by":"crossref","DOI":"10.1177\/1557988319856739","article-title":"Associations between masculine norms and health-care utilization in highly religious, heterosexual men","volume":"13","author":"JR Novak","year":"2019","journal-title":"Am J Mens Health"},{"issue":"9","key":"pgph.0004149.ref058","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002119","article-title":"Sex differences in tuberculosis burden and notifications in low- and middle-income countries: a systematic review and meta-analysis","volume":"13","author":"KC Horton","year":"2016","journal-title":"PLoS Med"},{"issue":"12","key":"pgph.0004149.ref059","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2023-014151","article-title":"Ending TB means responding to socially produced vulnerabilities of all genders","volume":"8","author":"B Ringwald","year":"2023","journal-title":"BMJ Glob Health"},{"issue":"2","key":"pgph.0004149.ref060","doi-asserted-by":"crossref","first-page":"149","DOI":"10.36858\/jkds.v9i2.306","article-title":"Risk assessment of adverse drug reactions in elderly patients with chronic diseases","volume":"9","author":"GA Hendra","year":"2021","journal-title":"JKDS"},{"issue":"7","key":"pgph.0004149.ref061","article-title":"The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis","volume":"15","author":"BS Kwon","year":"2020","journal-title":"PLoS One"},{"key":"pgph.0004149.ref062","doi-asserted-by":"crossref","first-page":"1029067","DOI":"10.3389\/fphar.2022.1029067","article-title":"Adverse drug reactions in an ageing PopulaTion (ADAPT) study: Prevalence and risk factors associated with adverse drug reaction-related hospital admissions in older patients","volume":"13","author":"C Cahir","year":"2023","journal-title":"Front Pharmacol"},{"issue":"1","key":"pgph.0004149.ref063","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2018-001029","article-title":"The impact of a cash transfer programme on tuberculosis treatment success rate: a quasi-experimental study in Brazil","volume":"4","author":"D J Carter","year":"2019","journal-title":"BMJ Glob Health"},{"key":"pgph.0004149.ref064","volume-title":"Evidence-based medicine: how to practice and teach EBM","author":"DL Sackett","year":"2001","edition":"2"}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0004149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T18:29:00Z","timestamp":1767032940000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0004149"}},"subtitle":[],"editor":[{"given":"Julia","family":"Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":64,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0004149","relation":{},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]}}}